FUNDING BY ZIOPHARM. Pursuant to Section 5.2 of the LICENSE AGREEMENT and subject to the terms and conditions of this AGREEMENT, during the TERM, ZIOPHARM agrees to fund the INITIAL TRANSFER COSTS and the DEVELOPMENT COSTS up to the amount established in accordance with this Section 5, and will reimburse UTMDACC for the INITIAL TRANSFER COSTS and DEVELOPMENT COSTS actually incurred by UTMDACC in accordance with this Section 5.
FUNDING BY ZIOPHARM. Pursuant to the 2015 R&D AGREEMENT and subject to the terms and conditions of this AGREEMENT, during the TERM, ZIOPHARM agrees to fund the DEVELOPMENT COSTS up to the amount and in the manner established in accordance with this Section 4, and will reimburse UTMDACC for the DEVELOPMENT COSTS actually incurred by UTMDACC in accordance with this Section 4. ZIOPHARM may set off against amounts committed for funding under this AGREEMENT those expenditures incurred and actually paid by ZIOPHARM in support of the TCR-T PROGRAM, including any amounts paid to third party contractors and/or landlords and/or any build-out costs for the LEASED FACILITY. ZIOPHARM shall provide UTMDACC with all documentation substantiating all such expenditures as reasonably requested by UTMDACC.
